Live News Categoriesmarket

SPTX.O (SPTX.O) News

Follow SPTX.O (SPTX.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SPTX.O Asset market Sector Markets 90 days 1 Updated Oct 07, 2026, 11:02 AM UTC Open live news feed

M Seaport Therapeutics doses first patient in Phase 2a trial for anxiety drug GlyphAgo Seaport Therapeutics has dosed the first patient in a Phase 2a clinical trial evaluating GlyphAgo (SPT-320), a novel prodrug of agomelatine, for adults with generalized anxiety disorder and sleep disturbance. Topline dat EQUITY | Oct 07, 2026, 11:02 AM UTC